Mitomycin (Mutamycin)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which is was used

Patient drug information

History of changes in FDA indication

  • 8/24/1981: Initial FDA approval

Also known as

  • Generic names: mitomycin-C, MTC
  • Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin